Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature
Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature
复制标题
DOI：
10.1016/j.pan.2014.07.002
复制
发表时间：
2014-09-01
期刊：
影响因子：
3.6
通讯作者：
Coppola, R.
中科院分区：
文献类型：
--
作者：
Valeri, S.;Borzomati, D.;Coppola, R.
新辅助治疗(化疗或放化疗)用于局部晚期胰腺导管腺癌(PDAC)患者。FOLFIRINOX现在被认为是治疗转移性胰腺癌患者的有效方法，也是局部晚期PDAC患者的一种有前途的选择。新辅助治疗后的完全病理反应是轶事，其对预后的影响完全不清楚。我们报告了一例局部晚期PDAC患者接受FOLFIRINOX治疗后出现完全病理反应的病例，并回顾了有关使用FOLFIRINOX治疗局部晚期PDAC的文献。版权所有(C)2014，IAP和EPC。由爱思唯尔印度有限公司出版，Reed Elsevier India Pvt.Ltd.的一个部门。保留所有权利。
Neoadjuvant treatments (chemo or chemoradiation therapy) are used for patients with locally advanced Pancreatic Ductal Adeno-Carcinoma (PDAC). FOLFIRINOX is now considered an effective treatment modality for patients with metastatic pancreatic cancer and a promising option for patients with locally advanced PDAC. Complete pathologic response after neoadjuvant therapies is anecdotic and its prognostic impact is completely unclear. We report the case of a complete pathological response after treatment with FOLFIRINOX in a patient affected by a locally advanced PDAC with a review of the literature regarding the use of FOLFIRINOX for locally advanced PDAC. Copyright (C) 2014, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.